Andere Sprachen Nautilus Biotechnology, Inc.

Aktien

A3CSCD

US63909J1088

NAUT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
2,34 ^USD	+2,63 %		-4,49 %	-21,74 %

10.06.	Transcript : Nautilus Biotechnology, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:40 AM
30.04.	Transcript : Nautilus Biotechnology, Inc., Q1 2024 Earnings Call, Apr 30, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	23.05.
Nautilus Biotechnology Reports First Quarter 2024 Financial Results	30.04.
Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30.04.
Nautilus Biotechnology : Reports First Quarter 2024 Financial Results - Form 8-K	30.04.
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024	11.04.
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024	11.04.
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results	28.02.
Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference	22.02.
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference	22.02.
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024	07.02.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award	30.11.
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award	30.11.
Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development	01.11.
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results	31.10.23
Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	31.10.23
Nautilus Biotechnology : Reports Third Quarter 2023 Financial Results - Form 8-K	31.10.23
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023	11.10.23
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023	11.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nautilus Biotechnology, Inc.

Aktien

A3CSCD

US63909J1088

NAUT

Andere Sprachen

Filter